Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer cell"
DOI: 10.1016/j.ccell.2017.11.013
Abstract: In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic "D-cyclin activating features (DCAF)" as particularly… read more here.
Keywords: predicting response; cdk4; genomic biomarkers; response selective ... See more keywords
Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00947
Abstract: Breast cancer is the most common tumor in women, and selective cyclin-dependent kinase (CDK) 4/6 inhibitors played an important role in the treatment of breast cancer. Therefore, discovering selective CDK4/6 inhibitors with great safety and… read more here.
Keywords: breast cancer; treatment; cancer; selective cdk4 ... See more keywords